Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 110

 Table of Contents  
Year : 2012  |  Volume : 4  |  Issue : 9  |  Page : 427-428

Seroconversion of hepatitis B virus surface antigen in chronic hepatitis B child treated with entecavir

Department of Liver Disease, Bethune International Peace Hospital, Shijiazhuang, Hebei, China

Date of Web Publication14-Sep-2012

Correspondence Address:
Dong Li
Department of Liver Disease, Bethune International Peace Hospital, Shijiazhuang, Hebei
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1947-2714.100996

Rights and Permissions

How to cite this article:
Li D, Wang J, Zhou J, Wang Y. Seroconversion of hepatitis B virus surface antigen in chronic hepatitis B child treated with entecavir. North Am J Med Sci 2012;4:427-8

How to cite this URL:
Li D, Wang J, Zhou J, Wang Y. Seroconversion of hepatitis B virus surface antigen in chronic hepatitis B child treated with entecavir. North Am J Med Sci [serial online] 2012 [cited 2022 Oct 2];4:427-8. Available from: https://www.najms.org/text.asp?2012/4/9/427/100996


Hepatitis B virus (HBV) infection in children possesses a higher rate of progression to chronic hepatitis, however, a consensus guideline for treatment has not been established so far. [1],[2] Entecavir as carbocyclic analog with inhibition of HBV replication [3] is shown encouraging effects in control of chronic HBV infection. [3] In the present article, we present seroconversion of hepatitis B virus surface antigen (HBsAg) by entecavir administrated in a young child with chronic hepatitis B.

A 4-year-old girl was presented in a history of chronic HBV infection for 2 years. The perinatal history indicated that her mother was a HBV carrier, and grandmother died of cirrhosis due to chronic hepatitis B. The patient was vaginally born, and was immunized with hepatitis B vaccine and high-titter immunoglobulin against HBV at birth.

During past 2 years, the patient had been administrated with Chinese herbal medicines. Because of unsatisfying theroputic effect, the patient was then transferred to our department. On admission, abdominal computed tomography (CT) scan demonstrated a normal size of the liver, but the spleen was enlarged in size. The laboratory tests showed that alanine aminotransferase (ALT) 92 U/L, aspartate transaminase (AST) 96 U/L, γ-glutamyl transpeptadase (GGT) 8 U/L, HBsAg positive, HBeAg positive, anti-HBV core antibody positive, and HBV DNA level 2.703 × 10 7 copies/mL. The autoimmune antibodies were absent, and serum markers for hepatitis A virus, hepatitis C virus, hepatitis E virus, cytomegalovirus, and Epstein Bar virus were negative. The patient was diagnosed with chronic hepatitis B with positive HBsAg.

After informed consent was obtained from her parents, the patient was started with oral administration of entecavir at dose of 0.16 mg once a day. During administration of entecavir, the patient was regularly monitored by tests of liver function, HBsAg and HBV DNA level, and hematologic system. Tests showed that ALT was declined 2 weeks after entecavir administrator, and was normalized 4 weeks after treatment. The level of HBV DNA decreased in 2 weeks, and negative 24 weeks after entecavir administration. Interestingly, we noticed that HBeAg seroconversion was started 12 weeks after the treatment, and HBsAg became negative 48 weeks after treatment, followed by HBsAg seroconversion 72 weeks after treatment. Entecavir was terminated at 192 nd week when liver function and HBV DNA were back to normal.

Entecavir was tolerated well in this little patient, and nephrotoxicity or myopathy were not noticed during the treatment. The patient has so far been followed-up for a period of 96 weeks since the termination of entecavir. The patient has positive anti-HBs, anti-HBe, anti-HBc, and normal liver function [Table 1]. The girl is well and in healthy condition now.
Table 1: Variations of laboratory tests before and aft ertreatment of entecavir

Click here to view

The ultimate goal of antiviral treatment in chronic HBV infection is to eradicate replicating HBV. HBV requires HBsAg to propagate infection and cause disease. Entecavir is a nucleoside analog with therapeutic effect on chronic HBV, [4],[5],[6],[7] and has been shown to decrease HBsAg in animal research. [8] Although potential effects of entecavir on chronic HBV infection were reported in some other studies, [3],[4],[5],[6] those studies had no involved lowering of HBsAg or HBsAg seroconversion. The satisfied outcome observed in our little girl patient using entecavir might be the first case, specifically lowering HBsAg or HBsAg seroconversion, in the reported literatures. Large sample are, however, needed to evaluate entecavir in term of clinical efficacy in children with chronic HBV.

  References Top

1.Alberti A, Brunetto MR, Colombo M, Craxi A. Recent progress and new trends in the treatment of hepatitis. J Med Virol 2002;67:458-62.  Back to cited text no. 1
2.Lok AS, McMohan BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.  Back to cited text no. 2
3.Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory HbeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49.  Back to cited text no. 3
4.Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;50:1064-71.  Back to cited text no. 4
5.Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology 2011;54:91-100.  Back to cited text no. 5
6.Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011;106:1766-73.  Back to cited text no. 6
7.Keating GM. Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs 2011;71:2511-29.  Back to cited text no. 7
8.Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-45.  Back to cited text no. 8


  [Table 1]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Article Tables

 Article Access Statistics
    PDF Downloaded3101    
    Comments [Add]    

Recommend this journal